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Abstract: The adaptive optics scanning light ophthalmoscope (AOSLO) allows
visualization of microscopic structures of the human retina in vivo. In this
work, we demonstrate its application in combination with oral and intravenous
(IV) fluorescein angiography (FA) to the in vivo visualization of the human
retinal microvasculature. Ten healthy subjects ages 20 to 38 years were
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imaged using oral (7 and/or 20 mg/kg) and/or IV (500 mg) fluorescein. In
agreement with current literature, there were no adverse effects among the
patients receiving oral fluorescein while one patient receiving IV fluorescein
experienced some nausea and heaving. We determined that all retinal
capillary beds can be imaged using clinically accepted fluorescein dosages and
safe light levels according to the ANSI Z136.1-2000 maximum permissible
exposure. As expected, the 20 mg/kg oral dose showed higher image
intensity for a longer period of time than did the 7 mg/kg oral and the 500
mg IV doses. The increased resolution of AOSLO FA, compared to
conventional FA, offers great opportunity for studying physiological and
pathological vascular processes.

1 - Introduction
Fluorescein angiography (FA) is the standard clinical tool for
assessing retinal and choroidal vascular disease. Since its introduction
in 1961 by Novotny and Alvis [1], its use has continued to grow, with
more than 1.2 million public procedures reported in 2011 by Medicare
[2]. FA reveals important pathological features of common vascular
conditions including microaneurysms, vascular leakage, capillary nonperfusion and neovascularization. In a variety of less common
diseases, such as sickle cell retinopathy, hereditary macular diseases
and retinal tumors, clinicians rely on FA to reveal characteristic
patterns which help facilitate diagnosis and monitor treatment
response [3].
Despite its ubiquity in the modern eye care practice, intravenous
(IV) FA is an invasive procedure and is associated with infrequent but
potentially severe adverse reactions, and even rare anaphylactoid
responses and death [4–8]. In order to acquire the early filling
sequence, the photographer must image the eye within seconds
following dye injection to capture its first appearance in the retinal
vasculature. For diseases where early filling information is not critical,
several investigators have demonstrated that oral administration of
fluorescein allows a more extended imaging period [9–14]. Conditions
as diverse as diabetic retinopathy, cystoid macular edema, central
serous retinopathy and papilledema have been successfully imaged
using oral fluorescein with comparable quality to IV fluorescein [9,11–
13,15–19]. Oral administration may be especially suitable for children
and for patients with poor venous access [9,10,20]. More importantly,
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side effects reported with oral administration of fluorescein have been
fewer and milder [15,21], although isolated cases of anaphylactoid
reactions have been reported [22,23].
The ability to image the retinal microvasculature longitudinally
in vivo is important for improving our understanding of physiological
and pathological processes. It may also allow earlier recognition of
pathology at stages where successful intervention may be possible and
facilitate comparison of response to different treatment modalities.
Conventional FA provides a wide-field view of the retinal vasculature,
but its transverse and axial resolution is severely limited by ocular
monochromatic aberrations. Histological comparisons have shown that
fundus FA incompletely depicts the capillary networks [24]. Adaptive
optics ophthalmoscopy has improved significantly over the past
decade, enabling extraordinary microscopic views of retinal structures.
Using the adaptive optics scanning light ophthalmoscope (AOSLO), in
vivo studies of normal and pathological retinal microstructure have
explored the photoreceptor mosaic [25,26], retinal pigment epithelium
[27,28], nerve fiber layer [29] and microvasculature. More recently,
motion contrast processing techniques applied to AOSLO have
improved the visualization of retinal capillaries and micro-angiopathic
features [30–33]. A variety of image processing methods that create
image contrast from blood flow have also been applied to image sets
acquired using retinal functional imager [34–36], optical coherence
tomography (OCT) [37–42] and adaptive optics OCT [43] to visualize
the retinal vasculature. Furthermore, additional non-invasive
techniques have been successfully applied to imaging the retinal
microvasculature including entoptic view [44–46] and adaptive optics
flood-illumination [47,48]. Studies to demonstrate the clinical utility of
these techniques are ongoing [41].
Although the use of FA with the AOSLO has been demonstrated
in primates [27,49] and rodents [50,51], it has not yet been explored
in living human subjects. In this proof-of-concept manuscript, we
report on the use of AOSLO FA for the in vivo visualization of normal
human retinal microvasculature. We discuss imaging methodology,
including instrument parameters, light safety, fluorescein dosage,
fluorescein route of administration, and imaging window for sufficient
fluorescence signal intensity.
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2 - Methods
2.1 Human subjects
Ten subjects, 20 to 38 years of age (mean age 27, median age
25) with no significant past medical or ocular histories were recruited.
Written informed consent was obtained after the nature and potential
risks of the procedure were explained. This study adhered to the
tenets of the Declaration of Helsinki and was approved by the
Institutional Review Board of the New York Eye and Ear Infirmary.

2.2 Fluorescein
Fluorescein came in 5 mL sterile vials containing 100 mg/mL
fluorescein (AK-FLUOR 10%, Akorn, Inc., Lake Forest, Illinois).
Previous authors have described various methods to make oral intake
more palatable, including mixing the fluorescein with sugar [21], using
encapsulated fluorescein pills [11,12,14,15] and mixing fluorescein
with citrus juice [10,13]. For our experiments, oral fluorescein was
administered with 50 mL of orange juice to mask its taste. The subject
was instructed to drink the mixture rapidly, and the time of
consumption was recorded as time zero. An additional 50 mL of orange
juice was provided to wash out the residual taste of the fluorescein. In
cases where IV administration of fluorescein was necessary,
administration was performed by a nurse.
For our experiments, the dose of fluorescein chosen was
estimated to balance the risk of any adverse systemic effects of
fluorescein with the estimated risk of retinal phototoxicity. For
example, while a smaller dose of fluorescein reduces the risk of an
adverse systemic reaction it produces a weaker fluorescence signal
requiring more retinal exposure to the excitation light. Conversely, a
larger dose of fluorescein carries a somewhat higher risk of adverse
reaction but reduces the required exposure to light. With these
requirements considered, a 20 mg fluorescein/kg body weight oral
dose was chosen as the baseline fluorescein dose for all experiments.
This dose is slightly lower than previously reported doses of 25 mg/kg
or greater that gave adequate fluorescence intensity on FA
[10,12,14,15].
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From the ten subjects imaged, the first five subjects were used
to gather preliminary data in optimizing the imaging protocol at 20
mg/kg oral fluorescein. As described in Table 1, our results present
data on the next five subjects in a series of five experiments using one
subject each. Experiments 2-4 were designed to evaluate comparisons
between fluorescein dosage, fluorescein route of administration, and
imaging modality, and thus required two separate imaging sessions.
Given that the half-life of fluorescein sodium is 267 minutes [52],
subjects from Experiments 2-4 were given a minimum five days’ time
between sessions to insure near total clearance of fluorescein from the
body.

2.3 Imaging protocol
Axial length measurements were collected (IOL Master, Carl
Zeiss Meditec AG, Jena, Germany) in order to calculate the AOSLO
image scale in microns per pixel. Pixel size calculations were based on
the Emsley schematic eye model [53]. Mydriasis and cycloplegia were
induced with 1 drop each of 2.5% phenylephrine hydrochloride
ophthalmic solution (Bausch&Lomb Inc., Tampa, FL) and 1%
tropicamide ophthalmic solution (Akorn Inc., Lake Forest, IL). Color
fundus photography (Topcon 3D OCT 2000, Topcon Corporation,
Tokyo, Japan) was performed to provide clinical context to the retinal
features seen with AOSLO imaging. Conventional scanning laser
ophthalmoscope (SLO) FA (Heidelberg Spectralis HRA-OCT, Heidelberg
Engineering Inc., Heidelberg, Germany) using oral fluorescein and FA
(TRC 50IX Retinal Camera, Topcon Corporation, Tokyo, Japan) using
IV fluorescein were performed for comparison with AOSLO FA (Table
1).
Stable and repeatable positioning of the subject’s eye during
AOSLO imaging was achieved using a bite bar attached to a translation
stage that allowed for fine transverse and axial adjustments. A dental
impression material was used to stabilize the subject’s jaw on the bite
bar (Splash! Putty, DenMat Holdings, LLC, Lompoc, California, USA).
Transverse alignment of the subject was achieved by centering the
pupil of the eye using the AOSLO wavefront sensor. Axial alignment
was then achieved by maximizing the image intensity in the
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reflectance channel and its uniformity across the field of view (FOV).
Subjects were instructed to direct their gaze towards a green internal
fixation target that was moved to allow imaging of specific locations of
interest on the retina. During each imaging session, the reflectance
channel was used to identify the regions of interest. Coordinates of
these locations were recorded so that they could be re-imaged
following fluorescein administration in the fluorescence channel.
Optimal focus, determined for both the fluorescein excitation and
reflectance channels, was recorded and used for all subsequent
imaging of the identified locations.
Previous studies have reported that maximum excitation signal
intensity occurs 15-60 minutes following oral administration of
fluorescein with visibility of pathologic features present up to 120
minutes [9,11–15]. Given this information, AOSLO FA imaging
sessions started at approximately 15 minutes post-administration of
fluorescein in all experiments. In Experiments 3 and 4, AOSLO FA
imaging began 15 minutes post-administration of fluorescein and
continued at 20-minute intervals until 115 minutes had elapsed.
During imaging, simultaneous segments of fluorescence and
reflectance images consisting of 120-200 frames each were recorded
at 15 frames per second using a 1°, 1.5° or 1.75° FOV. The gain of the
detector in both channels was maintained at a constant level during all
imaging sessions for all subjects. Throughout the imaging session,
subjects were encouraged to blink frequently to support their normal
tear film and were provided with short breaks of 3-5 minutes at
regular intervals or as needed.

2.4 AOSLO
The AOSLO used for this study was a replica of the one by
Dubra and Sulai [54], with the visible channel modified for
fluorescence imaging. The modification involved replacement of the
light source with a 488 nm diode laser (Lasos, Lasertechnick GmbH,
Jena, Germany), and the addition of an interferometric band-pass
optical filter centered at 525 nm with a 45 nm bandwidth in front of
the detector. The longitudinal chromatic aberration (LCA) present in
the human eye spreads the fluorescence focus along the optical axis
over a range of approximately 0.3 diopters. This was addressed by
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using a large (3.75 Airy disk diameter) confocal aperture. No attempt
was made to account for LCA variation across individuals.
Both the reflectance and fluorescence registered averaged
images with high signal-to-noise ratio were generated by applying the
frame-to-frame estimated eye motion calculated from the reflectance
images, using sequences of 40-100 raw frames [27,55]. Typically, it
took an examiner one minute to select 4-5 reference frames from each
video, and it took an additional minute for the software to create the
registered image averages. The registered image averages were then
tiled (Adobe Photoshop CS6, Adobe Systems, Inc., San Jose,
California, USA) to create larger fields of view.

2.5 Light safety
During AOSLO FA, the retina was simultaneously exposed to up
to three different light sources (488, 790 and 850 nm), which entered
the eye as superimposed (coaxial), near-collimated 7.75 mm diameter
beams. All three beams localized onto a single spot on the fundus,
which was rapidly scanned to form a 1.3, 1.95 or 2.3° square imaging
raster, using a 14.5 KHz horizontal resonant optical scanner and a 16
Hz vertical optical scanner. Synchronous modulation of the light
sources turned them on at the start of the imaging portion of each
horizontal line used for imaging when scanning from left to right. As a
result only the central 1.0 to 1.75° of the scanning raster were
exposed to light. The optical powers without modulation (i.e.,
continuous wave) measured at the cornea were 15 μW for the 850 nm
wavefront sensing superluminescent diode (SLD), 100 μW for the 790
nm imaging SLD and 32 μW for the 488 nm diode laser. During
imaging, the on/off modulation reduced the average powers delivered
to approximately 25% of their original values.
No retinal location was exposed to the combined light sources
for longer than 120 seconds. When immediately contiguous areas were
imaged, the exposures were reduced to a maximum of 30 seconds to
account for potential overlapping exposure of neighboring retinal
locations due to involuntary eye motion. All sources were considered
as lasers for the maximum permissible exposure (MPE) calculations,
which were performed using the ANSI standard for the safe use of
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lasers [56]. These imaging parameters, as described above, resulted
in light exposures 6 times below both the photochemical and the
thermal MPE limits.

3 - Results
In all 10 subjects, AOSLO FA was able to successfully resolve
the smallest capillaries. Retinal vessels to the level of quaternary
branches and capillary beds were clearly distinguishable from the rim
of the optic disc to the foveal avascular zone (FAZ). Throughout the
imaging session and during the six hours which followed, only one
subject reported experiencing any adverse effects. The subject
experienced transient nausea and heaving immediately following IV
injection of fluorescein, which resolved shortly thereafter. As with
conventional FA imaging, the intensity of the fluorescence in the
AOSLO FA images varied over time, location and across individuals.

3.1 Experiment 1: comparison of AOSLO FA vs.
conventional SLO FA using oral fluorescein
Images collected within 10 minutes of each other in a single
subject using conventional scanning laser ophthalmoscope (SLO) FA
and AOSLO FA, following oral administration of 20 mg/kg fluorescein,
illustrate the superior resolution provided by the use of adaptive optics
(Fig. 1). Numerous fine capillaries are revealed in the AOSLO FA
images, which are not visible in the conventional SLO FA images.

3.2 Experiment 2: comparison of AOSLO FA using oral
fluorescein vs. conventional IV FA
Conventional IV FA using a fundus camera was performed on a subject
using 500 mg IV fluorescein. On a different visit, AOSLO FA images
were collected, starting 15 minutes post-administration of oral (20
mg/kg) fluorescein. 1.75° FOV AOSLO images were collected
contiguously to complete a 6° box centered at the fovea. Comparison
of the AOSLO FA montage with conventional IV FA shows that AOSLO
FA reveals much finer vasculature with appreciably higher contrast
(Fig. 2).
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3.3 Experiment 3: comparison of oral versus IV
fluorescein in AOSLO FA
To assess the strength of the fluorescence signal as a function of
time in oral versus IV administration, we imaged the same patient with
AOSLO FA in two different imaging sessions. Oral fluorescein (20
mg/kg) was used in the first session, and IV fluorescein (500 mg) was
used in the second session. AOSLO imaging began 15 minutes postadministration of fluorescein and continued at 20-minute intervals until
115 minutes had elapsed (Fig. 3). The mean pixel value of the
resulting images was used as a metric for fluorescence signal. As
shown in Fig. 3, oral and IV fluorescein provided similar image
intensities at 17 minutes and 18 minutes after administration
respectively. At 35 minutes or more after administration, oral
fluorescein provided higher peak image intensity and more sustained
fluorescence compared to IV fluorescein. It should be noted that peak
intensity in the case of IV administration probably occurred before the
first image of the sequence.

3.4 Experiment 4: AOSLO FA oral fluorescein dosimetry
In an effort to minimize potential adverse reactions to orally
administered fluorescein, we explored the feasibility of visualizing
retinal vasculature using a lower dose (7 mg/kg vs. 20 mg/kg). Figure
4 shows images from one area of interest that was imaged at both the
high and low dose of fluorescein in two separate imaging sessions. As
previously described, AOSLO imaging began 15 minutes postadministration of fluorescein and continued at 20-minute intervals until
115 minutes had elapsed. Similarly, the mean pixel value of the
resulting images was used as a metric for fluorescence signal. The
sequence of images shown in Fig. 4 demonstrate that comparable
images were produced by both doses, although as expected, the
fluorescence signal, as measured by the mean pixel values, scaled
with the dose. Both doses, however, appear sufficient in most cases to
allow for AOSLO FA imaging for as long as an hour, although this could
vary significantly across visits and individuals.
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3.5 Experiment 5: resolution of overlying peripapillary
capillary beds using AOSLO FA
We examined the ability of AOSLO FA to axially resolve
overlying capillary beds at 4 peripapillary locations (Fig. 5(A) insets B,
C, D and E) using 20 mg/kg oral fluorescein. AOSLO FA was able to
resolve the radial peripapillary capillary bed (Fig. 5(B2), 5(C2), 5(D2)
and 5(E2)) within the highly reflective surface of the nerve fiber layer
(Fig. 5(B1), (C1), (D1) and (E1)). As the focus shifted toward the
outer retina, deeper capillary beds were resolved (Fig. 5(B3), 5(C3),
5(D3) and 5(E3)). Images of the deeper capillary beds appear
somewhat noisier due to background haze from the out-of-focus
fluorescence signal of the choroidal vasculature.

4 - Discussion
We have demonstrated that AOSLO FA can reveal microscopic
detail of the retinal vasculature at safe light exposures in human
subjects using oral or IV fluorescein. With both methods of fluorescein
administration, AOSLO FA was able to visualize the retinal capillary
beds at all attempted retinal locations and at multiple depths with
qualitatively comparable contrast and sharpness. While both the 7
mg/kg oral dose and 500 mg IV dose successfully visualized the fine
capillaries, the 20 mg/kg dose provided a stronger, more sustained
fluorescence signal. Thus, 20 mg/kg oral administration of fluorescein
seems more suitable for surveying larger retinal areas, given the
current limited FOV (typically < 3°) of the AOSLO. It is important to
note that, compared to conventional FA, the small FOV of the AOSLO
limits its ability to acquire the early filling sequence of fluorescein over
a large retinal area. Fluorescence peak and disappearance varied both
across individuals and visits with both oral and IV fluorescein. Even
with this variability, we were able to achieve up to an hour of sufficient
signal intensity when using 20 mg/kg oral fluorescein.
Consistent with previous reports [15,21], adverse reactions to
fluorescein occurred less frequently when administered orally. Only
one adverse reaction (nausea and heaving) occurred following IV
administration in this series, with none following oral administration.
Since isolated case reports have described rare but occasionally severe
Biomedical Optics Express, Vol. 4, No. 8 (August 2013): pg. 1305-1317. DOI. This article is © Optical Society of America
and permission has been granted for this version to appear in e-Publications@Marquette. Optical Society of America
does not grant permission for this article to be further copied/distributed or hosted elsewhere without the express
permission from Optical Society of America.

11

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

reactions to orally administered fluorescein, it is very important to
elicit any patient history of atopy or past reactions to fluorescein [57].
Precautionary measures in the imaging laboratory such as ready
access to a resuscitative crash cart are also recommended [5].
Currently, AOSLO FA appears to offer reasonable signal-to-noise
ratio, no image processing artifacts, axial sectioning, and neardiffraction-limited transverse and axial resolution. For an average eye
with effective focal length of approximately 17 mm and a pupil
diameter of 7.75 mm, AOSLO FA approaches an axial resolving limit of
20 μm, enabling it to resolve overlying capillary beds in the retina
[58]. However, a significant clinical limitation of AOSLO FA which must
be considered is that the potential transverse and axial resolution of
the AOSLO can only fully materialize with unobstructed large pupils.
Lower reflectance and fluorescence signal and/or poorer resolution
should be expected in subjects with small pupils and/or cataracts.
AOSLO image quality can also be affected by non-clear media, retinal
or anterior chamber inflammation and multifocal or diffractive
intraocular lens implants. Imaging the vasculature with conventional
(i.e., non-AO) OCT-based techniques, on the other hand, may be less
affected by cataracts because they do not require a large pupil,
although lower transverse resolution is to be expected. We believe that
new and developing microvascular imaging technologies, including
non-invasive motion contrast image processing techniques [34,35,37–
39,43], will prove to be synergistic with AOSLO FA and perhaps better
suited for fast non-invasive screening. Further studies are necessary to
determine the full advantages and limitations of these emerging
technologies relative to each other. AOSLO FA, although not likely to
replace conventional wide-field FA, offers great potential for studying
and quantifying retinal microvascular attributes such as vessel
diameter, branching pattern, tortuosity and capillary density in both
healthy and disease states. Much can be learned by applying already
developed metrics and geometrical descriptors for retinal and brain
vascular imaging [59–64]. Coupled with methods to quantify
microvascular attributes, we believe that AOSLO FA will provide
insights into retinal vascular diseases, and has the potential to become
a clinical tool in detecting disease, disease progression, and tissue
response to traditional and emerging treatment modalities.
Furthermore, through studying and characterizing the retinal
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microvascular changes that occur in systemic cardiovascular disease
with AOSLO FA, we can potentially gain a deeper understanding of
pathological processes and end-organ damage that occur in diabetes,
hypertension and vascular occlusion [65,66].
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Table 1. AOSLO FA Experiments

Description of fluorescein dosages, routes of administration and imaging
modalities used during imaging sessions in Experiments 1-5. Experiments 1
and 5 consisted of a single imaging session.

Biomedical Optics Express, Vol. 4, No. 8 (August 2013): pg. 1305-1317. DOI. This article is © Optical Society of America
and permission has been granted for this version to appear in e-Publications@Marquette. Optical Society of America
does not grant permission for this article to be further copied/distributed or hosted elsewhere without the express
permission from Optical Society of America.

20

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

Fig. 1. Conventional SLO FA image (A) taken 20 minutes after oral
administration of 20 mg/kg fluorescein, with two areas of interest (A insets B
and C) approximately 5° from the fovea. These same areas were magnified
and contrast stretched (B1 and C1) for comparison with AOSLO FA images of
the corresponding areas (B2 and C2), collected 30 minutes after oral
fluorescein administration. The scale bar represents 100 μm and applies to all
images other than image A.
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Fig. 2. Conventional IV FA image of the FAZ was magnified and contrast
stretched (A) for comparison with an AOSLO FA image montage of the same
region (B). The AOSLO scale bar represents 500 μm.
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Fig. 3. Comparison of AOSLO FA image sequences after oral or IV fluorescein
administration, showing a retinal area approximately 5° inferotemporal from
the fovea. Fluorescein was administered at time zero. Mean pixel value was
calculated for each image and then normalized to the maximum value of the
oral and IV image series to generate the intensity percentages, presented on
the top right corner of each image. All images were then contrast stretched to
make optimal use of the gray scale while avoiding saturation. The contraststretched images are presented in this figure. The scale bar represents 100
μm.

Fig. 4. Comparison of AOSLO FA image sequences between 20 mg/kg and 7
mg/kg oral administration of fluorescein, showing a retinal area
approximately 5° superior-nasal from the fovea. Mean pixel values were
calculated for each image and then normalized to the maximum value of the
oral and IV image series to generate the intensity percentages, presented on
the top right corner of each image. All images were then contrast stretched to
make optimal use of the gray scale while avoiding saturation. The contraststretched images are presented in this figure. The scale bar represents 100
μm.
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Fig. 5. Conventional SLO FA image acquired approximately 30 minutes after
oral fluorescein administration (A) showing four peripapillary locations chosen
for AOSLO imaging (A insets B, C, D and E). The reflectance AOSLO images of
these small areas, focused on the nerve fiber layer (B1, C1, D1 and E1), show
large blood vessels, capillaries and nerve fiber bundles. The corresponding
AOSLO FA images recorded at the same focus (B2, C2, D2 and E2)
approximately 15 minutes after oral fluorescein administration show only
vasculature, revealing the radial peripapillary capillary bed with high contrast
and detail. Peripapillary capillaries (B2, C2, D2 and E2) can be seen radiating
parallel to the nerve fibers (B1, C1, D1 and E1). Capillary free zones can be
seen surrounding arteries (B2, C2 and lower E2) and not veins (D2 and upper
E2). AOSLO FA images focused closer to the outer retina (B3, C3, D3 and E3)
show additional non-radial capillaries (arrow heads). These retinal capillaries
can be seen deriving from the same retinal arteries (arrows) that supply the
peripapillary capillaries. The scale bar represents 100 μm and applies to all
images other than image A.
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